Real-World Study of Once-Daily, Extended-Release Tacrolimus Versus Twice-Daily, Immediate-Release Tacrolimus in Kidney Transplantation: Clinical Outcomes and Healthcare Resource Utilization
ConclusionReal-world clinical outcomes and healthcare resource utilization were similar with ER-T and IR-T. Larger studies will need to investigate the trend toward fewer BCAR events, and increased graft survival with ER-T.FundingAstellas Pharma Global Development, Inc.Plain Language SummaryPlain language summary available for this article.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Drugs & Pharmacology | Kidney Transplant | Kidney Transplantation | Pharmaceuticals | Prograf | Study | Tacrolimus | Transplant Surgery | Transplants | Urology & Nephrology